English
Regional settings| Spread | 0.09 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 11.41 |
| Open | 11.15 |
| 1-Year Change | -1.85% |
| Day's Range | 11.09 - 11.44 |
Zynex, Inc. designs, manufactures and markets medical devices, which treats chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation. The Company’s medical devices are small, portable, battery operated and include an electrical pulse generator, which is connected to the body via electrodes. Its primary product is the NexWave device. The NexWave is marketed to physicians and therapists by its field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.
BRIEF: For the fiscal year ended 31 December 2021, Zynex Inc. revenues increased 63% to $130.3M. Net income increased 88% to $17.1M. Revenues reflect Supplies increase of 59% to $93.7M, Devices increase of 72% to $36.6M. Net income benefited from Rental Expense decrease of 51% to $2M (expense), Stock-based Compensation in SGA decrease of 36% to $1.4M (expense), Rental Expense decrease of 33% to $1.2M (expense).
Common Stock $.001 Par, 03/11, 100M auth., 30,631,946 issd. Insiders own 61.68%. 07/08, Name changed from Zynex Medical Holdings, Inc.
